Reshma Rangwala
Analyst
Clinical Lead
Equibles does not estimate personal net worth.
About Reshma Rangwala
Reshma Rangwala is recorded as Analyst at Clinical Lead. Reshma Rangwala has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Karyopharm Therapeutics Inc. on August 13, 2026. The companies whose calls Reshma Rangwala spoke on are classified in the Healthcare sector.
Reshma Rangwala on recent calls
“As Richard discussed, we believe Selenexor has the potential to fundamentally change the treatment of patients with myelofibrosis.”
“So, you know, thank you for the invitation. This is always a lovely conference. You know, Century, as Richard mentioned was truly a highlight for us, you know, not only at ASCO, but, you know, at CarioPharm.”
“Before we dive into myelofibrosis and endometrial cancer, I want to take a step back and ground everyone in the biology of XPO1 inhibition, and why we believe this novel mechanism has the potential to meaningfully improve outcomes for patients across both diseases, as outlined on slide 7.”
Affiliation history
-
Clinical Lead
Analyst
Source not stated
Current